Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04681690Recruiting

German National Registry for NSS

Role: lead

NCT01717677Not ApplicableTerminated

Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk

Role: lead

NCT01215071Not ApplicableCompleted

Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA

Role: lead

NCT01555086Not ApplicableUnknown

Prospective Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy

Role: lead

NCT01216371Phase 2Unknown

Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)

Role: lead

NCT01215266Phase 2Terminated

Sorafenib in Urothelium Cancer of Bladder

Role: lead

NCT00146276Phase 3Unknown

Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer

Role: lead

All 7 trials loaded